What do we know about India’s Covaxin vaccine?

The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0.5 ml) intramuscularly at a 28-day interval. Adverse reactions were obtained by web-based questionnaires or telephone calls seven days after each vaccine dose. Detection of antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was done four weeks after the second dose of the vaccine. We enrolled 103 previously naturally infected and 627 uninfected HCWs. The mean time for vaccination after the first nasopharyngeal SARS-CoV-2 positivity was 64 days (range: 15–136 days) in previously naturally infected HCWs. Among the previously naturally infected HCWs, 41 (40%) were asymptomatic, 52 (50%) had mild upper respiratory tract infections, 10 (105) had pneumonia, and only 6 (5%) were hospitalized. Any reported adverse reactions, either from the first dose or the second dose of vaccine administration, did not differ between previously infected and uninfected HCWs. Anti-RBD antibody titers were obtained in 50 (51%) of 103 previously infected HCWs and 142 (23%) of 627 uninfected HCWs. Anti-RBD antibody titers were significantly higher in HCWs with a previous natural infection (median 1220 AU/ml, range: 202–10328 AU/mL) than in uninfected HCWs (median: 913 AU/ml, range: 2.8–15547 AU/mL, p = .032). CoronaVac administration was safe and may elicit higher antibody responses in previously naturally infected individuals.

show abstract

“…Bharat Biotech released interim efficacy data on March 3, 2021, which showed a clinical efficacy of 81%. 15 …”

Section: Discussionmentioning

confidence: 99%

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers

Soysal

Gönüllü²,

Karabayır

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Covaxin vaccine was manufactured by the Indian Bharat Biotechnology Company in collaboration with the Indian Council of Medical Research and National Institute of Virology [21]. The COV has been granted permission in India for restricted use in emergency situations despite being in phase 3 of clinical trials [128,129]. The Indian company also signed a partnership with the Pennsylvania-based company Ocugen for marketing the vaccine in the United States [130].…”

Section: Covaxin Vaccine (Cov; Bharat Biotech Vaccine Bbv152)mentioning

confidence: 99%

A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development

et al. 2021

View full text Add to dashboard Cite

Since the beginning of 2020, the world has been in a race to develop vaccines that can control the COVID-19 pandemic. More than 250 projects have been initiated for this purpose, but only 14 of them have been authorized for use, despite being in phase 3 clinical trials. More than 40 other vaccines are also in phase 1/2 clinical trials and show promising outcomes. Regarding the appropriate choice of vaccines for each country or region, we reviewed the currently used vaccines in light of the different influencing parameters. These factors include the mode of action, dosage protocol, age group of the vaccinee, side effects, storage conditions, mounted immune response, and cost. Technically, there are seven types of vaccines developed against SARS-CoV-2: messenger RNA (mRNA), nonreplicating and replicating vectors, inactivated viruses, protein subunits, viral-like particles, DNA vaccines, and live attenuated vaccines. The mRNA type is being used for the first time in humans. Unfortunately, mutated variants of SARS-CoV-2 have started to appear worldwide, and researchers are investigating the effects of the currently used vaccines on them. There are many concerns regarding the long-term protection afforded by these vaccines and their side effects, and whether they require future modifications to be effective against the mutated variants. The development of new vaccines using more advanced technology is paramount for overcoming the difficulties in controlling the COVID-19 pandemic across the world.

show abstract

“…India launched its vaccine drive on 16 January 2021, mostly relying on Covishield, a version of the Oxford-AstraZeneca vaccine produced by the Serum Institute of India. A smaller number of people get India’s domestically developed Covaxin, manufactured by Bharat Biotech 13. The government had set a target of vaccinating 250 million people by July.…”

Section: How Will the Crisis Affect India’s Vaccine Rollout?mentioning

confidence: 99%

Why is India having a covid-19 surge?

Thiagarajan¹

2021

BMJ

Self Cite

View full text Add to dashboard Cite

India's infections set new pandemic records in April, with more than 300 000 positive tests each day for a week. Kamala Thiagarajan looks at the many unanswered questions Kamala ThiagarajanOn 26 April India saw the highest daily tally of new SARS-CoV-2 infections ever recorded in the world, 360 960, taking its pandemic total to 16 million cases, second only to the US, and more than 200 000 deaths.The devastating second wave comes a year after the country imposed one of the most rigid lockdown restrictions in the world-and just three months since its health ministry declared that infections and mortality were at an all time low. 1

show abstract

What do we know about India’s Covaxin vaccine?

Cited by 54 publications

References 5 publications

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers

A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development

Why is India having a covid-19 surge?

Contact Info

Product

Resources

About